Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
14 nov. 2023 05h28 HE
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 08h00 HE
|
Vaccinex, Inc.
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
09 nov. 2023 16h05 HE
|
Athira Pharma, Inc.
Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments...
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
09 nov. 2023 12h58 HE
|
RetinalGeniX Technologies, Inc.
RetinalGeniX Announces Therapeutic Solutions Being Developed for Dry Age-Related Macular Degeneration
and Alzheimer’s Syndrome.
Athira Pharma to Participate in Jefferies London Healthcare Conference
08 nov. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
08 nov. 2023 05h45 HE
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC and AVANIA CRO CONTRACT to GUIDE the DEVELOPMENT of TWO DRUG THERAPIES and the RETINALCAM™ IMAGE VISUALIZATION DEVICE
Encore Creativity for Older Adults Receives $1M Donation for Brain Health Initiatives
02 nov. 2023 09h52 HE
|
Encore Creativity for Older Adults
Encore Creativity for Older Adults receives gift pledge of $1M to expand music programs for those with cognitive change
AAPA, PA Foundation, Cleveland Clinic, and Davos Alzheimer’s Collaborative Release Early Cognitive Assessment Toolkit
01 nov. 2023 09h26 HE
|
American Academy of PAs
ALEXANDRIA, VA, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA), PA Foundation (PAF), Cleveland Clinic, and Davos Alzheimer’s Collaborative (DAC) today publicly...
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31 oct. 2023 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
26 oct. 2023 09h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a...